Israel Abebrese Sefah1,2, Olayinka O Ogunleye3,4, Darius Obeng Essah1, Sylvia A Opanga5, Nadia Butt6, Annie Wamaitha6, Anastasia Nkatha Guantai7, Ibrahim Chikowe8, Felix Khuluza8, Dan Kibuule9, Lahya Nambahu9, Abdullahi Rabiu Abubakar10, Ibrahim Haruna Sani11, Zikria Saleem12, Aubrey C Kalungia13, Thuy Nguyen Thi Phuong14, Mainul Haque15, Salequl Islam16, Santosh Kumar17, Jacqueline Sneddon18, Joshua Wamboga19, Janney Wale20, Nenad Miljković21, Amanj Kurdi22,23, Antony P Martin24,25, Brian Godman22,26,27,28. 1. Pharmacy Department, Keta Municipal Hospital, Ghana Health Service, Keta-Dzelukope, Ghana. 2. Pharmacy Practice Department of Pharmacy Practice, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana. 3. Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Nigeria. 4. Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Nigeria. 5. Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, University of Nairobi, Nairobi, Kenya. 6. Pharmaceutical Society of Kenya, Nairobi, Kenya. 7. Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya. 8. Pharmacy Department, College of Medicine, Blantyre, Malawi. 9. Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia. 10. Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Bayero University, Kano, Nigeria. 11. Unit of Pharmacology, College of Health Sciences, Yusuf Maitama Sule University, Kano, Nigeria. 12. Faculty of Pharmacy, University of Lahore, Lahore, Pakistan. 13. Department of Pharmacy, University of Zambia, Lusaka, Zambia. 14. Pharmaceutical Administration and PharmacoEconomics, Hanoi University of Pharmacy, Hanoi, Vietnam. 15. Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur, Malaysia. 16. Department of Microbiology, Jahangirnagar University, Dhaka, Bangladesh. 17. Department of Periodontology and Implantology, Karnavati University, Gandhinagar, India. 18. Healthcare Improvement Scotland, Glasgow, United Kingdom. 19. Uganda Alliance of Patients' Organizations (UAPO), Kampala, Uganda. 20. Independent Consumer Advocate, Brunswick, VIC, Australia. 21. Institute of Orthopaedic Surgery "Banjica", University of Belgrade, Belgrade, Serbia. 22. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom. 23. Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq. 24. Faculty of Health and Life Sciences, Brownlow Hill, Liverpool, United Kingdom. 25. QC Medica, York, United Kingdom. 26. School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa. 27. School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. 28. Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Abstract
Background: Countries across Africa and Asia have introduced a variety of measures to prevent and treat COVID-19 with medicines and personal protective equipment (PPE). However, there has been considerable controversy surrounding some treatments including hydroxychloroquine where the initial hype and misinformation led to shortages, price rises and suicides. Price rises and shortages were also seen for PPE. Such activities can have catastrophic consequences especially in countries with high co-payment levels. Consequently, there is a need to investigate this further. Objective: Assess changes in utilisation, prices, and shortages of pertinent medicines and PPE among African and Asian countries since the start of pandemic. Our approach: Data gathering among community pharmacists to assess changes in patterns from the beginning of March until principally the end of May 2020. In addition, suggestions on ways to reduce misinformation. Results: One hundred and thirty one pharmacists took part building on the earlier studies across Asia. There were increases in the utilisation of principally antimalarials (hydroxychloroquine) and antibiotics (azithromycin) especially in Nigeria and Ghana. There were limited changes in Namibia and Vietnam reflecting current initiatives to reduce inappropriate prescribing and dispensing of antimicrobials. Encouragingly, there was increased use of vitamins/immune boosters and PPE across the countries where documented. In addition, generally limited change in the utilisation of herbal medicines. However, shortages have resulted in appreciable price increases in some countries although moderated in others through government initiatives. Suggestions in Namibia going forward included better planning and educating patients. Conclusion: Encouraging to see increases in the utilisation of vitamins/immune boosters and PPE. However, concerns with increased utilisation of antimicrobials needs addressing alongside misinformation, unintended consequences from the pandemic and any appreciable price rises. Community pharmacists and patient organisations can play key roles in providing evidence-based advice, helping moderate prices through improved stock management, and helping address unintended consequences of the pandemic.
Background: Countries across Africa and Asia have introduced a variety of measures to prevent and treat COVID-19 with medicines and personal protective equipment (PPE). However, there has been considerable controversy surrounding some treatments including hydroxychloroquine where the initial hype and misinformation led to shortages, price rises and suicides. Price rises and shortages were also seen for PPE. Such activities can have catastrophic consequences especially in countries with high co-payment levels. Consequently, there is a need to investigate this further. Objective: Assess changes in utilisation, prices, and shortages of pertinent medicines and PPE among African and Asian countries since the start of pandemic. Our approach: Data gathering among community pharmacists to assess changes in patterns from the beginning of March until principally the end of May 2020. In addition, suggestions on ways to reduce misinformation. Results: One hundred and thirty one pharmacists took part building on the earlier studies across Asia. There were increases in the utilisation of principally antimalarials (hydroxychloroquine) and antibiotics (azithromycin) especially in Nigeria and Ghana. There were limited changes in Namibia and Vietnam reflecting current initiatives to reduce inappropriate prescribing and dispensing of antimicrobials. Encouragingly, there was increased use of vitamins/immune boosters and PPE across the countries where documented. In addition, generally limited change in the utilisation of herbal medicines. However, shortages have resulted in appreciable price increases in some countries although moderated in others through government initiatives. Suggestions in Namibia going forward included better planning and educating patients. Conclusion: Encouraging to see increases in the utilisation of vitamins/immune boosters and PPE. However, concerns with increased utilisation of antimicrobials needs addressing alongside misinformation, unintended consequences from the pandemic and any appreciable price rises. Community pharmacists and patient organisations can play key roles in providing evidence-based advice, helping moderate prices through improved stock management, and helping address unintended consequences of the pandemic.
Authors: Natalie Schellack; Morné Strydom; Michael S Pepper; Candice L Herd; Candice Laverne Hendricks; Elmien Bronkhorst; Johanna C Meyer; Neelaveni Padayachee; Varsha Bangalee; Ilse Truter; Andrea Antonio Ellero; Thulisa Myaka; Elysha Naidoo; Brian Godman Journal: Antibiotics (Basel) Date: 2022-03-25
Authors: Edwin N Wangari; Peter Gichuki; Angelyne A Abuor; Jacqueline Wambui; Stephen O Okeyo; Henry T N Oyatsi; Shadrack Odikara; Benard W Kulohoma Journal: AAS Open Res Date: 2021-03-29
Authors: Ayukafangha Etando; Adefolarin A Amu; Mainul Haque; Natalie Schellack; Amanj Kurdi; Alian A Alrasheedy; Angela Timoney; Julius C Mwita; Godfrey Mutashambara Rwegerera; Okwen Patrick; Loveline Lum Niba; Baffour Boaten Boahen-Boaten; Felicity Besong Tabi; Olufunke Y Amu; Joseph Acolatse; Robert Incoom; Israel Abebrese Sefah; Anastasia Nkatha Guantai; Sylvia Opanga; Ibrahim Chikowe; Felix Khuluza; Dan Kibuule; Francis Kalemeera; Ester Hango; Jennie Lates; Joseph Fadare; Olayinka O Ogunleye; Zikria Saleem; Frasia Oosthuizen; Werner Cordier; Moliehi Matlala; Johanna C Meyer; Gustav Schellack; Amos Massele; Oliver Ombeva Malande; Aubrey Chichonyi Kalungia; James Sichone; Sekelani S Banda; Trust Zaranyika; Stephen Campbell; Brian Godman Journal: Healthcare (Basel) Date: 2021-12-13